FDA grants priority review to futibatinib for advanced cholangiocarcinoma

The FDA granted priority review to futibatinib for treatment of certain patients with cholangiocarcinoma.The designation applies to use of the agent by previously treated patients with locally advanced or metastatic disease who harbor FGFR2 gene rearrangements, including gene fusions.Futibatinib (Taiho Pharmaceutical) is an oral selective and irreversible small-molecule inhibitor of FGFR1, 2, 3 and 4.Approximately estimated 8,000 people in the United States are diagnosed each year with cholangiocarcinoma, a rare cancer of the bile ducts of the liver. An estimated 10% to 16% of those patientsRead More

Generated by Feedzy